In March, Pfizer announced it would spend $43 billion to acquire antibody-drug conjugate pioneer Seagen. After a brief slump in popularity, other biopharma giants like AstraZeneca, BioNTech and Bristol-Myers Squibb are betting big on ADCs.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,